Skip to Main Content

Coding Analysis for Labs (CAL) Tracking Sheet for PSA (Addition of ICD-9-CM 600.10, Nodular prostate without urinary obstruction and 600.11, with urinary obstruction, as covered indications) (CAG-00331N)

CMS received an external request to add ICD-9-CM 600.10 Nodular prostate without urinary obstruction, and ICD-9-CM 600.11 Nodular prostate with urinary obstruction, as covered indications for the Prostate Specific Antigen (PSA) NCD at 190.31 of the NCD Manual.

The narrative covered indications for the PSA NCD state, “PSA is of proven value in differentiating benign from malignant disease in men with lower urinary tract signs and symptoms as well as with patients with palpably abnormal prostate glands on physician exam and in patients with other laboratory or imaging studies that suggest the possibility of a malignant prostate disorder.”

We believe code 600.10, Nodular prostate without urinary obstruction, and code 600.11, Nodular prostate with urinary obstruction, flow from the narrative. We are seeking public comment on the addition of codes 600.10 and 600.11 to the "ICD-9-CM Codes Covered By Medicare" list for the PSA NCD.

The regulation for maintaining code lists in the negotiated NCDs for clinical diagnostic laboratory services states that codes on the covered list flow from the existing NCD narratives of covered indication. The regulation was published February 25, 2005 in the Federal Register, Vol.70, No. 37 and can be viewed at

Diagnostic Laboratory Tests
Requestor Name(s)Lori Cushing, Coding Supervisor, HRSRedington Fairview General Hospital, Skowhegan, Maine
Formal Request Accepted and Review Initiated05/31/2006
Expected NCA Completion Date08/31/2006
Public Comment Period05/31/2006 - 06/30/2006
Decision Memo Released07/17/2006
Comments for this CAL:View Public Comments
Lead Analyst(s)
  • Maria Ciccanti, RN
Lead Medical Officer(s)
  • Jim Rollins, MD, MSHA, PhD

May 31, 2006

CMS accepts a request to add ICD-9-CM codes 600.10 and 600.11 as covered indications in the PSA national coverage determination list of covered indications.

The 30-day public comment period begins with this date, and ends after 30 calendar days. CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the test under consideration.

July 17, 2006

Posted decision memo.